KRAS and non-small cell lung carcinoma: Nevertheless, patients with EGFR+ NSCLC had a significantly longer post-metastatic bone disease survival compared with the other patients (median 15 mo [EGFR+], 9.0 mo [KRAS+], and 3.2 mo [EGFR/KRAS wild type]), (EGFR+ - KRAS+, p = 0.049, EGFR+ - EGFR+/KRAS+ wildtype, p = 0.004).1